Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Seiichi Okabe

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL T315I Point Mutation

Journal of Hematology and Oncology

English

Combination Therapy With Copanlisib and ABL Tyrosine Kinase Inhibitors Against Philadelphia Chromosome-Positive Resistant Cells

Oncotarget

Oncology

2016

English

Related publications

Small Interfering RNA Against BCR-ABL Transcripts Sensitize Mutated T315I Cells to Nilotinib

Haematologica

Hematology

2010

English

Broad Spectrum Alkynyl Inhibitors of T315I BCR-Abl

Bioorganic and Medicinal Chemistry Letters

Clinical Biochemistry

Pharmaceutical Science

Drug Discovery

2010

English

The Gatekeeper Mutation T315I Confers Resistance Against Small Molecules by Increasing or Restoring the ABL-kinase Activity Accompanied by Aberrant Transphosphorylation of Endogenous BCR, Even in Loss-Of-Function Mutants of BCR/ABL

English

BCR-ABL-transformed GMP as Myeloid Leukemic Stem Cells

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2008

English

Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I

English

Disruption of the BCR-Abl/Hsp90 Protein Complex: A Possible Mechanism to Inhibit BCR-Abl-Positive Human Leukemic Blasts by Novobiocin

English

A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl

Journal of Medicinal Chemistry

Drug Discovery

Molecular Medicine

2010

English

MT1-MMP as a Downstream Target of BCR-ABL/ABL Interactor 1 Signaling: Polarized Distribution and Involvement in BCR-ABL-stimulated Leukemic Cell Migration

English

Oligomerization Inhibition, Combined With Allosteric Inhibition, Abrogates the Transformation Potential of T315i-Positive BCR/ABL

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Seiichi Okabe

Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL T315I Point Mutation

Combination Therapy With Copanlisib and ABL Tyrosine Kinase Inhibitors Against Philadelphia Chromosome-Positive Resistant Cells

Related publications

Small Interfering RNA Against BCR-ABL Transcripts Sensitize Mutated T315I Cells to Nilotinib

Broad Spectrum Alkynyl Inhibitors of T315I BCR-Abl

The Gatekeeper Mutation T315I Confers Resistance Against Small Molecules by Increasing or Restoring the ABL-kinase Activity Accompanied by Aberrant Transphosphorylation of Endogenous BCR, Even in Loss-Of-Function Mutants of BCR/ABL

BCR-ABL-transformed GMP as Myeloid Leukemic Stem Cells

Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I

Disruption of the BCR-Abl/Hsp90 Protein Complex: A Possible Mechanism to Inhibit BCR-Abl-Positive Human Leukemic Blasts by Novobiocin

A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl

MT1-MMP as a Downstream Target of BCR-ABL/ABL Interactor 1 Signaling: Polarized Distribution and Involvement in BCR-ABL-stimulated Leukemic Cell Migration

Oligomerization Inhibition, Combined With Allosteric Inhibition, Abrogates the Transformation Potential of T315i-Positive BCR/ABL